141 related articles for article (PubMed ID: 21790243)
1. Cost of care for lung cancer in the first year after diagnosis in Iran.
Mohagheghi MA; Mousavi-Jarrahi Y; Mosavi-Jarrahi A
Asian Pac J Cancer Prev; 2011; 12(4):1013-5. PubMed ID: 21790243
[TBL] [Abstract][Full Text] [Related]
2. Management and costs of treating lung cancer patients in a university hospital.
Dedes KJ; Szucs TD; Bodis S; Joerger M; Lowy A; Russi EW; Steinert HC; Weder W; Stahel RA
Pharmacoeconomics; 2004; 22(7):435-44. PubMed ID: 15137882
[TBL] [Abstract][Full Text] [Related]
3. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.
Hillner BE; McDonald MK; Desch CE; Smith TJ; Penberthy LT; Maddox P; Retchin SM
J Clin Oncol; 1998 Apr; 16(4):1420-4. PubMed ID: 9552046
[TBL] [Abstract][Full Text] [Related]
4. Cost-components of lung cancer care within the first three years after initial diagnosis in context of different treatment regimens.
Schwarzkopf L; Wacker M; Holle R; Leidl R; Günster C; Adler JB; Huber RM
Lung Cancer; 2015 Nov; 90(2):274-80. PubMed ID: 26384433
[TBL] [Abstract][Full Text] [Related]
5. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
7. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
[TBL] [Abstract][Full Text] [Related]
8. The cost of lung transplantation in Iran.
Abbasi-Dezfouli A; Pojhan S; Behgam-Shadmehr M; Najafizadeh K; Ghorbani F; Lorgard-Dezfuli-Nejad M; Assari S
Ann Transplant; 2009; 14(2):30-3. PubMed ID: 19487791
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
[TBL] [Abstract][Full Text] [Related]
11. Cost analysis of lung cancer management in South Western Sydney.
Kang S; Koh ES; Vinod SK; Jalaludin B
J Med Imaging Radiat Oncol; 2012 Apr; 56(2):235-41. PubMed ID: 22498199
[TBL] [Abstract][Full Text] [Related]
12. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
[TBL] [Abstract][Full Text] [Related]
13. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea.
Park YS; Kim SH; Park SK; Park BJ; Kim YT; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Shim YS; Yang SC
Lung Cancer; 2010 May; 68(2):299-304. PubMed ID: 19646776
[TBL] [Abstract][Full Text] [Related]
14. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
15. Direct treatment costs for patients with lung cancer from first recurrence to death in france.
Braud AC; Lévy-Piedbois C; Piedbois P; Piedbois Y; Livartovski A; Le Vu B; Trédaniel J; Reboul F; Brewer Y; Talbi S; Blanchon F; Paschen B; Durand-Zaleski I
Pharmacoeconomics; 2003; 21(9):671-9. PubMed ID: 12807368
[TBL] [Abstract][Full Text] [Related]
16. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
Hornberger J; Hirsch FR; Li Q; Page RD
Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
[TBL] [Abstract][Full Text] [Related]
17. First data on direct costs of lung cancer management in Morocco.
Tachfouti N; Belkacemi Y; Raherison C; Bekkali R; Benider A; Nejjari C
Asian Pac J Cancer Prev; 2012; 13(4):1547-51. PubMed ID: 22799364
[TBL] [Abstract][Full Text] [Related]
18. Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective.
Kreys ED; Koeller JM
J Oncol Pract; 2013 Sep; 9(5):e241-7. PubMed ID: 23943896
[TBL] [Abstract][Full Text] [Related]
19. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and lung cancer clinical trials.
Du W; Reeves JH; Gadgeel S; Abrams J; Peters WP
Cancer; 2003 Oct; 98(7):1491-6. PubMed ID: 14508837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
